Similarly, anti-CTLA-4 agents approved for treatment of melanoma have been tested in advanced stage SCLC and NSCLC, though results for SCLC are thus far inconclusive [22,23]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.